申请人:Taisho Pharmaceutical Co., Ltd.
公开号:EP2730573A1
公开(公告)日:2014-05-14
A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (OX) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.
一种由式(IA)代表的化合物或其药学上可接受的盐,其作用依赖于奥曲肽受体(OX)拮抗活性,可用于治疗或预防睡眠障碍、抑郁症、焦虑症、精神分裂症、药物依赖性、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、头痛、偏头痛、疼痛、胃肠病等疾病、恐慌症、精神分裂症、药物依赖、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、头痛、偏头痛、疼痛、胃肠道疾病、癫痫、炎症、免疫相关疾病、内分泌相关疾病和高血压。